Clinical evaluation of Yiqifumai combined with Alprostadil in the treatment of cardiac insufficiency with unstable angina pectoris / 中华老年医学杂志

ABSTRACT

Objective To assess the therapeutic effects of Yiqifumai combined with Alprostadil injection on patients with chronic cardiac insufficiency and angina pectoris.Methods One hundred and fifty patients with heart dysfunction (NYHA [Ⅱ-Ⅲ) and angina pectoris were randomly divided into three groups,the control group (n=50),the Yiqifumai group (n=50),and the Yiqifumai plus Alprostadil group (n=50).Parameters including clinical effectiveness,electrocardiograph (ECG),heart function and hemodynamics were evaluated.Results The overall clinical effectiveness rate in the Yiqifumai plus Alprostadil group (94 ％) was higher than those in the Yiqifumai group (78 ％) and the control group (54％) (P＜0.05 for both).The overall effectiveness rate in ECG changes was higher in the Yiqifumai plus Alprostadil group (84％) than in the Yiqifunai group (58％) and the control group (42％) (P＜0.05 for both).While no significant difference in the left ventricular ejection fraction (LVEF) was found among the three groups before treatment,evident improvement in LVEF was observed in the Yiqifunai group and the Yiqifumai plus Alprostadil group 14 days after treatment,compared with pre-treatment data [(49±9)％ vs.(40±10)％ and (59±9)％ vs.(41±10) ％,respectively; P＜0.05 for both].However,there was no significant difference between the two groups (P＞0.05).There was no improvement in LVEF in the control group after treatment (P ＞0.05).No difference in hemodynamic parameters,including cardiac output,cardiac index and left ventricular stroke work index,was found among the three groups before treatment (P＞0.05),but they showed improvement in the Yiqifunai group and the Yiqifumai plus Alprostadil group after treatment (P＜0.05 for both),with greater improvement in the latter group.The improvement was not significant in the control group before and after treatment (P＞0.05).Conclusions Yiqifumai combined with Alprostadil in the treatment of cardiac insufficiency with unstable angina pectoris has advantages in improving clinical symptoms,heart function and hemodynamics.